Pharmacogenomics in Alzheimer's disease

A genome-wide association study of response to cholinesterase inhibitors

Filippo Martinelli-Boneschi, Giacomo Giacalone, Giuseppe Magnani, Gloria Biella, Elisabetta Coppi, Roberto Santangelo, Paola Brambilla, Federica Esposito, Sara Lupoli, Francesca Clerici, Luisa Benussi, Roberta Ghidoni, Daniela Galimberti, Rosanna Squitti, Annamaria Confaloni, Giuseppe Bruno, Sabrina Pichler, Manuel Mayhaus, Matthias Riemenschneider, Claudio Mariani & 6 others Giancarlo Comi, Elio Scarpini, Giuliano Binetti, Gianluigi Forloni, Massimo Franceschi, Diego Albani

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We conducted a genome-wide association study in a cohort of 176 Italian Alzheimer's disease (AD) patients with extreme phenotype of response to cholinesterase inhibitors. Patients were classified into responders in case of positive, stable, or ≤1 worsening of mini-mental state examination score and into nonresponders if >3 points worsening during a median follow-up of 0.85 years of treatment. Forty-eight single-nucleotide polymorphisms were selected for replication in 198 additional AD-treated patients. By using the dichotomous response trait and a quantitative trait approach (change of mini-mental state examination), a nominal replication and evidence of association when combining data were achieved for 2 single-nucleotide polymorphisms associated with response to treatment: rs6720975A (pcombined = 2.9 × 10-5, beta regression coefficient: 1.61) and rs17798800A (pcombined = 6.8 × 10-6, odds ratio = 0.38, 95% confidence interval = 0.25-0.58). Rs6720975 maps in the intronic region of PRKCE, a protein kinase involved in several cellular functions, whereas rs17798800 is intergenic and, according to expression quantitative trait locus (eQTL) analysis, it acts as a cis-regulator of NBEA, an A kinase-anchoring protein playing a substantial role in the maturation of the nervous system. Despite its limitations, this project paves the way for the application of personalized medicine in AD patients and for collaborative efforts in this field.

Original languageEnglish
JournalNeurobiology of Aging
Volume34
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Genome-Wide Association Study
Pharmacogenetics
Cholinesterase Inhibitors
Alzheimer Disease
Protein Kinases
Single Nucleotide Polymorphism
Precision Medicine
Quantitative Trait Loci
Nervous System
Odds Ratio
Confidence Intervals
Phenotype
Therapeutics

Keywords

  • Acetylcholinesterase inhibitors
  • Alzheimer's disease
  • Genetics
  • Genome-wide association study
  • Pharmacogenomics

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Ageing
  • Developmental Biology
  • Geriatrics and Gerontology

Cite this

Pharmacogenomics in Alzheimer's disease : A genome-wide association study of response to cholinesterase inhibitors. / Martinelli-Boneschi, Filippo; Giacalone, Giacomo; Magnani, Giuseppe; Biella, Gloria; Coppi, Elisabetta; Santangelo, Roberto; Brambilla, Paola; Esposito, Federica; Lupoli, Sara; Clerici, Francesca; Benussi, Luisa; Ghidoni, Roberta; Galimberti, Daniela; Squitti, Rosanna; Confaloni, Annamaria; Bruno, Giuseppe; Pichler, Sabrina; Mayhaus, Manuel; Riemenschneider, Matthias; Mariani, Claudio; Comi, Giancarlo; Scarpini, Elio; Binetti, Giuliano; Forloni, Gianluigi; Franceschi, Massimo; Albani, Diego.

In: Neurobiology of Aging, Vol. 34, No. 6, 06.2013.

Research output: Contribution to journalArticle

Martinelli-Boneschi, F, Giacalone, G, Magnani, G, Biella, G, Coppi, E, Santangelo, R, Brambilla, P, Esposito, F, Lupoli, S, Clerici, F, Benussi, L, Ghidoni, R, Galimberti, D, Squitti, R, Confaloni, A, Bruno, G, Pichler, S, Mayhaus, M, Riemenschneider, M, Mariani, C, Comi, G, Scarpini, E, Binetti, G, Forloni, G, Franceschi, M & Albani, D 2013, 'Pharmacogenomics in Alzheimer's disease: A genome-wide association study of response to cholinesterase inhibitors', Neurobiology of Aging, vol. 34, no. 6. https://doi.org/10.1016/j.neurobiolaging.2012.12.008
Martinelli-Boneschi, Filippo ; Giacalone, Giacomo ; Magnani, Giuseppe ; Biella, Gloria ; Coppi, Elisabetta ; Santangelo, Roberto ; Brambilla, Paola ; Esposito, Federica ; Lupoli, Sara ; Clerici, Francesca ; Benussi, Luisa ; Ghidoni, Roberta ; Galimberti, Daniela ; Squitti, Rosanna ; Confaloni, Annamaria ; Bruno, Giuseppe ; Pichler, Sabrina ; Mayhaus, Manuel ; Riemenschneider, Matthias ; Mariani, Claudio ; Comi, Giancarlo ; Scarpini, Elio ; Binetti, Giuliano ; Forloni, Gianluigi ; Franceschi, Massimo ; Albani, Diego. / Pharmacogenomics in Alzheimer's disease : A genome-wide association study of response to cholinesterase inhibitors. In: Neurobiology of Aging. 2013 ; Vol. 34, No. 6.
@article{96c5626430eb43ea890e1c05f58c7f5a,
title = "Pharmacogenomics in Alzheimer's disease: A genome-wide association study of response to cholinesterase inhibitors",
abstract = "We conducted a genome-wide association study in a cohort of 176 Italian Alzheimer's disease (AD) patients with extreme phenotype of response to cholinesterase inhibitors. Patients were classified into responders in case of positive, stable, or ≤1 worsening of mini-mental state examination score and into nonresponders if >3 points worsening during a median follow-up of 0.85 years of treatment. Forty-eight single-nucleotide polymorphisms were selected for replication in 198 additional AD-treated patients. By using the dichotomous response trait and a quantitative trait approach (change of mini-mental state examination), a nominal replication and evidence of association when combining data were achieved for 2 single-nucleotide polymorphisms associated with response to treatment: rs6720975A (pcombined = 2.9 × 10-5, beta regression coefficient: 1.61) and rs17798800A (pcombined = 6.8 × 10-6, odds ratio = 0.38, 95{\%} confidence interval = 0.25-0.58). Rs6720975 maps in the intronic region of PRKCE, a protein kinase involved in several cellular functions, whereas rs17798800 is intergenic and, according to expression quantitative trait locus (eQTL) analysis, it acts as a cis-regulator of NBEA, an A kinase-anchoring protein playing a substantial role in the maturation of the nervous system. Despite its limitations, this project paves the way for the application of personalized medicine in AD patients and for collaborative efforts in this field.",
keywords = "Acetylcholinesterase inhibitors, Alzheimer's disease, Genetics, Genome-wide association study, Pharmacogenomics",
author = "Filippo Martinelli-Boneschi and Giacomo Giacalone and Giuseppe Magnani and Gloria Biella and Elisabetta Coppi and Roberto Santangelo and Paola Brambilla and Federica Esposito and Sara Lupoli and Francesca Clerici and Luisa Benussi and Roberta Ghidoni and Daniela Galimberti and Rosanna Squitti and Annamaria Confaloni and Giuseppe Bruno and Sabrina Pichler and Manuel Mayhaus and Matthias Riemenschneider and Claudio Mariani and Giancarlo Comi and Elio Scarpini and Giuliano Binetti and Gianluigi Forloni and Massimo Franceschi and Diego Albani",
year = "2013",
month = "6",
doi = "10.1016/j.neurobiolaging.2012.12.008",
language = "English",
volume = "34",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Pharmacogenomics in Alzheimer's disease

T2 - A genome-wide association study of response to cholinesterase inhibitors

AU - Martinelli-Boneschi, Filippo

AU - Giacalone, Giacomo

AU - Magnani, Giuseppe

AU - Biella, Gloria

AU - Coppi, Elisabetta

AU - Santangelo, Roberto

AU - Brambilla, Paola

AU - Esposito, Federica

AU - Lupoli, Sara

AU - Clerici, Francesca

AU - Benussi, Luisa

AU - Ghidoni, Roberta

AU - Galimberti, Daniela

AU - Squitti, Rosanna

AU - Confaloni, Annamaria

AU - Bruno, Giuseppe

AU - Pichler, Sabrina

AU - Mayhaus, Manuel

AU - Riemenschneider, Matthias

AU - Mariani, Claudio

AU - Comi, Giancarlo

AU - Scarpini, Elio

AU - Binetti, Giuliano

AU - Forloni, Gianluigi

AU - Franceschi, Massimo

AU - Albani, Diego

PY - 2013/6

Y1 - 2013/6

N2 - We conducted a genome-wide association study in a cohort of 176 Italian Alzheimer's disease (AD) patients with extreme phenotype of response to cholinesterase inhibitors. Patients were classified into responders in case of positive, stable, or ≤1 worsening of mini-mental state examination score and into nonresponders if >3 points worsening during a median follow-up of 0.85 years of treatment. Forty-eight single-nucleotide polymorphisms were selected for replication in 198 additional AD-treated patients. By using the dichotomous response trait and a quantitative trait approach (change of mini-mental state examination), a nominal replication and evidence of association when combining data were achieved for 2 single-nucleotide polymorphisms associated with response to treatment: rs6720975A (pcombined = 2.9 × 10-5, beta regression coefficient: 1.61) and rs17798800A (pcombined = 6.8 × 10-6, odds ratio = 0.38, 95% confidence interval = 0.25-0.58). Rs6720975 maps in the intronic region of PRKCE, a protein kinase involved in several cellular functions, whereas rs17798800 is intergenic and, according to expression quantitative trait locus (eQTL) analysis, it acts as a cis-regulator of NBEA, an A kinase-anchoring protein playing a substantial role in the maturation of the nervous system. Despite its limitations, this project paves the way for the application of personalized medicine in AD patients and for collaborative efforts in this field.

AB - We conducted a genome-wide association study in a cohort of 176 Italian Alzheimer's disease (AD) patients with extreme phenotype of response to cholinesterase inhibitors. Patients were classified into responders in case of positive, stable, or ≤1 worsening of mini-mental state examination score and into nonresponders if >3 points worsening during a median follow-up of 0.85 years of treatment. Forty-eight single-nucleotide polymorphisms were selected for replication in 198 additional AD-treated patients. By using the dichotomous response trait and a quantitative trait approach (change of mini-mental state examination), a nominal replication and evidence of association when combining data were achieved for 2 single-nucleotide polymorphisms associated with response to treatment: rs6720975A (pcombined = 2.9 × 10-5, beta regression coefficient: 1.61) and rs17798800A (pcombined = 6.8 × 10-6, odds ratio = 0.38, 95% confidence interval = 0.25-0.58). Rs6720975 maps in the intronic region of PRKCE, a protein kinase involved in several cellular functions, whereas rs17798800 is intergenic and, according to expression quantitative trait locus (eQTL) analysis, it acts as a cis-regulator of NBEA, an A kinase-anchoring protein playing a substantial role in the maturation of the nervous system. Despite its limitations, this project paves the way for the application of personalized medicine in AD patients and for collaborative efforts in this field.

KW - Acetylcholinesterase inhibitors

KW - Alzheimer's disease

KW - Genetics

KW - Genome-wide association study

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=84875240626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875240626&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2012.12.008

DO - 10.1016/j.neurobiolaging.2012.12.008

M3 - Article

VL - 34

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 6

ER -